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Abstract
Introduction: Immunohistochemical expression of B-cell lymphoma 
2 (BCL-2) is seen variably in invasive ductal carcinoma. This study 
was conducted to determine the frequency of BCL-2 expression 
in different histologic grades of invasive ductal carcinoma. 
Materials and Methods: A cross-sectional study was conducted in the 
Department of Pathology at Shaukat Khanum Memorial Cancer Hospital 
and Research Centre, Pakistan, on subjects with invasive ductal carcinoma 
of various histologic grades. Immunohistochemistry was done using 
the BCL-2 antibody in all cases. The frequency of BCL-2-positive cases in 
different histologic grades was noted. Post-stratification, the Chi-square test 
was applied. P ≤ 0.05 was considered statistically significant. Results: All 52 
subjects were female (100%) with a mean age of 47.58 ± 1.43 years. BCL-2 
expression was observed in 28 (53.85 %) subjects with breast cancer. Out of 
33 participants with Grade III, 13 (39.39 %) participants were positive for BCL-
2 expression. Among 18 subjects with Grade II, 14 (77.78 %) subjects were 
positive for BCL-2 expression. Reduced frequency of BCL-2 expression was 
observed with increasing histologic grade (i.e., more in low-grade tumours 
and less in Grade III), but the difference was statistically not significant. 
Conclusion: A differential expression of BCL-2 was observed across 
different grades of invasive ductal carcinoma. However, the difference was 
not statistically significant.
Key words: B-cell lymphoma-2, breast cancer, histologic grades, 
immunohistochemistry, invasive ductal carcinoma
Introduction
According to the World Health Organisation, 
breast cancer is the most common malignancy in 
women worldwide. It affects 2.1 million women 
every year. In 2018, breast cancer accounted for 
almost 15% of cancer-associated mortalities. The 
incidence is higher in developed countries and 
is increasing globally.[1] Among Asian countries, 
Pakistani women are next to Israeli Jews in 
developing breast cancer, accounting for 34.6% 
of female malignancies.[2] Breast cancer is a 
heterogeneous disease with a wide variation 
in morphological features, grades, hormone 
receptor status and molecular genetics.[3] Different 
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etiological factors contribute to the development 
of breast cancer. However, among these, the 
three major causative factors in breast cancer 
development are genetic factors, hormonal 
influences and environmental factors. Almost 40% 
of hereditary breast carcinomas are associated 
with BRCA1/BRCA2 gene mutations.[4] Among the 
various subtypes of breast carcinoma, invasive 
ductal carcinoma is the most frequently diagnosed 
subtype.[5]
The process of carcinogenesis is the result of the 
accumulation of genetic variants that play a role 
in cell proliferation and apoptosis, thus deciding 
the fate of the lesion.[6] B-cell lymphoma 2 (BCL-2) 
protein is a member of the BCL family that regulates 
apoptosis. Its oncogenic role is supported by its 
increased expression in lymphomas and various 
tumours, including breast cancer.[7]
In a study conducted by Ruibal et al., higher 
expression of BCL-2 is seen in Grade I and II 
tumours of invasive ductal carcinoma than Grade 
III tumours.[8] A large study conducted by Dawson 
et al. demonstrated BCL-2 overexpression in 73% 
of breast cancer and served as an independent 
prognostic factor.[9] In another study carried out in 
China, BCL-2 expression was noted in 84.61% of 
Grade I breast cancers, 58.69% in Grade II of breast 
cancer and 12.50% in Grade III of breast cancer.[10]
The rationale of this study was to determine the 
expression of BCL-2 in different histologic grades 
of breast cancer in Pakistani women as BCL-2 is a 
prognostic marker as well as a potential target for 
new therapies.[11]
Materials and Methods
A cross-sectional study was conducted in the 
Department of Pathology at Shaukat Khanum 
Memorial Cancer Hospital and Research Centre, 
Lahore, Pakistan. The Institutional Review Board 
(IRB) approved a waiver of informed consent for 
this study (EX-25-10-19-01). Fifty-two patients with 
invasive ductal carcinoma were selected by non-
probability consecutive sampling for 5 months 
extending from 1 December 2017 to 30 April 2018. 
Patients diagnosed with invasive ductal carcinoma 
of breast on incisional biopsy, excisional biopsy 
or mastectomy specimens were included in the 
study. Poorly fixed samples, scanty biopsies or 
post-therapy biopsies were not included.
Patient demographics as age and gender, the 
grade of breast cancer, were recorded. Histological 
grading was done blindly by two experienced 
pathologists with a special interest in breast 
pathology, as per Nottingham’s-Bloom-Richardson 
System modification. It assesses three parameters 
that is, tubule formation, nuclear pleomorphism 
and mitotic count, giving a score of 1–3 for each. A 
total score out of 9 is used to ascertain the grade of 
the tumour. BCL-2 immunostaining was performed 
on sections of paraffin blocks using Roche BCL-2 
antibody, clone 124. Tissue sections were taken on 
a glass slide and subjected to Ventana automated 
immunohistochemistry analyser (Benchmark ultra). 
Results of immunohistochemistry were interpreted 
and approved by the consultant pathologists 
independently to avoid bias. BCL-2 demonstrated 
cytoplasmic and/or membranous staining of the 
cells. The cutoff value was taken at 10%, cases with 
<10% tumour cells staining with BCL-2 or without 
any staining were considered negative while 
staining of more than or equal to 10% tumour cells 
was taken as positive.[12]
Statistical analysis was performed using SPSS 
version 20 software (SPSS Inc., Chicago, IL, USA). 
Frequency and percentage were calculated for 
gender, expression of BCL-2 and grades of breast 
cancer. Mean ± standard deviation was calculated 
for qualitative data. Age and tumour grades 
effect were checked using stratification. The post-
stratification Chi-square test was applied to study 
the significance. P ≤ 0.05 was considered to be 
statistically significant.
Results
Fifty-two female subjects with invasive ductal 
carcinoma of different grades were included in 
the study. The mean age of the participants was 
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47.58 ± 1.43 years. Most of the subjects (32.69 %) 
fell in the age range of 41–50 years [Table 1]. Out 
of 52 subjects that were included in this study, 
there was 1 (1.92%) subject with Grade I breast 
cancer, 18 (34.62%) subjects with Grade II breast 
cancer and 33 (63.46%) subjects with Grade III 
breast cancer [Figure 1]. On the evaluation of BCL-
2 by immunohistochemistry, 28 (53.85%) cases 
showed positive BCL-2 expression and 24 (46.15%) 
cases either did not show any staining for BCL-2 or 
stained <10% of the tumour cells [Figure 2]. These 
samples were considered to be negative. Regarding 
the expression of BCL-2 in different histologic 
grades of invasive ductal carcinoma, Grade I breast 
cancer exhibited diffuse expression of BCL-2 in 
tumour cells. Out of 18 Grade II invasive ductal 
breast carcinoma, 14 (77.78%) tumours expressed 
BCL-2, while 4 (22.22%) were negative for BCL-2 
expression. Among Grade III tumours, 20 (60.61%) 
were negative for BCL-2 expression and 13 (39.39%) 
showed positive BCL-2 expression [Figures 3 and 4].
The post-stratification Chi-square test of significance 
suggested that the differences in the expression 
of BCL-2 in different grades of breast carcinoma 
were statistically not significant (P = 0.06) [Table 2]. 
The highest expression of BCL-2 was seen in the 
41–50 years age group (58.82%) and the lowest 
expression of BCL-2 was found in the 21–30 years 
age group [Table 3].
Discussion
Prognosis of breast cancer is dependent on various 
factors including grade, stage and hormone 
receptor status.[13] The expression of BCL-2 in breast 
cancer and its correlation with different breast cancer 
parameters that is, histologic grade, stage, receptor 
status and its role as an independent prognostic 
marker, has been studied in various parts of the 
world. Literature has shown variable results among 
different studies. This study aimed to determine the 
expression of BCL-2 in different histologic grades of 
breast cancer in Pakistani women.
The current study showed that BCL-2 expression 






















No. % No. %
I (n=1) 1 100 0 0
II (n=18) 14 77.78 4 22.22






No. % No. %
21–30 (n=3) 1 33.33 2 66.67
31–40 (n=13) 6 46.15 7 53.85
41–50 (n=17) 10 58.82 7 41.18
51–60 (n=16) 8 50 8 50
61–70 (n=3) 3 100 0 0
P-value 0.46
investigation (53.85%). This is in concordance 
with the research carried out by Eom et al., in 
which BCL-2 expression was observed in 53.8% 
of cases.[12] Similarly, Mdzin et al. reported BCL-
2-positive expression in 40.7% of cohort.[14] The 
study also concluded that BCL-2 was expressed in 
normal breast epithelium adjacent to the tumour, 
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suggesting that BCL-2 expression protects normal 
epithelial cells from undergoing apoptosis and 
increases their proliferation.
In a study carried by Joensuu et al.,[15] 25% of the 
subjects showed no immunoreactivity for BCL-2 
protein in malignant epithelial cells, 29% had weak 
expression (+) and 29% showed moderate staining 
(++). In comparison, 17% exhibited strong staining 
(+++) for BCL-2 protein. Overall, 75% of subjects 
were positive for BCL-2 expression. In a study by 
Dawson et al., BCL-2 expressions were seen among 
73% of subjects and were found to be a predictor of 
better prognosis.[9] It was suggested by Mdzin et al. 
that the observed variation of BCL-2 expression 
in different researches might be attributed to 
sampling technique, the difference in analysis and 
the cutoff value.[14]
Since BCL-2 blocks programmed cell death 
(apoptosis) and contributes to the accumulation 
of malignant cells, its overexpression raises the 
possibility of aggressive tumour behaviour. 
Genetic alteration of the BCL-2 gene, present 
on chromosome 18, is crucial in developing 
Figure 1: Hematoxylin and eosin (H and E) stained slide 
of invasive ductal carcinoma Grade II, ×400
Figure  2: Positive staining of B-cell lymphoma-2 
(cytoplasmic and membranous) in invasive ductal 
carcinoma Grade II, ×200
Figure 3: Hematoxylin and eosin (H and E) stained slide 
of invasive ductal carcinoma Grade III, ×400
Figure  4: Negative staining for B-cell lymphoma-2 in 
invasive ductal carcinoma Grade III, ×200
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chemoresistant neoplasms as follicular lymphoma. 
However, in breast cancer, positive BCL-2 
expression is associated with better differentiation 
that is, lower grades, low proliferation index and ER 
positivity.[16] One of these attributes of BCL-2 that is, 
more expression in low-grade tumours than high-
grade tumours, was observed in our study. The 
majority of the participants belonged to histologic 
Grades III and II (63.46% and 34.62%, respectively). 
A different frequency of histologic grading of the 
subjects had been observed by Dawson et al. who 
document that frequency of Grades I–III was 14%, 
41% and 45%, respectively.[9]
In this study, the single Grade I breast cancer 
demonstrated strong diffuse BCL-2 expression, 
while Grade II and III cancers expressed BCL-2 with 
a frequency of 77.78% and 39.39%, respectively 
(P > 0.05). In a study by Yu et al., the expression 
of BCL-2 across Grades I–III of ductal carcinoma 
was 84.61%, 58.69% and 12.50%, respectively, 
and the difference was statistically significant (P 
< 0.01).[9] However, Mdzin et al. reported that 
the difference in the BCL-2 expression in Grades 
I–III was statistically not significant. In a study by 
Lee et al. which was conducted to determine 
the reciprocal expression of BCL-2 and p53 in 
ductal carcinoma, it was found that the BCL-2+/
p53- pattern predominates in histological Grade 
I (77.4%) and Grade II tumours (59.3%) with a 
rarity of BCL-2 expression in Grade III carcinomas 
(6.3%).[17] Conversely, BCL-2-/p53+ expression was 
observed in 50% of Grade III carcinomas, while 
3.2% and 11.1% expression were noted in Grade I 
and II tumours, respectively. This pattern of BCL-2/
p53 expression by tumours might help in depicting 
the response to therapy and prognosis. It was also 
established that BCL-2 expression correlates with 
other prognostic factors, and its expression could 
be oestrogen dependent.
Mdzin et al. have observed a decrease in BCL-2 
expression with a progressive increase in 
histopathologic grades.[14] We also observed 
a declining pattern of BCL-2 expression with 
increasing grades of the tumour, but the results 
were not significant.
On stratification of data with respect to different age 
groups, the BCL-2 expression was highest among 
the participants in the fourth and fifth decades of 
life. It was the least among subjects in the second 
and sixth decades of life. However, this difference 
was statistically not significant P > 0.05). Similar 
differences in BCL-2 expression within different age 
groups were also observed by Yu et al.18 Contrary 
to the findings of the present study, the difference 
was found to be statistically significant (P < 0.01). 
They also found that in menopausal women with 
breast cancer, the positive expression of BCL-2 was 
calculated at 88.9% in Grade I tumours, 73.7% in 
Grade II tumours and 0.0% in Grade III tumours 
(P > 0.05). Therefore, a declining trend of BCL-2 
expression with an increase in histological grade 
was noted.
This study has certain limitations. All of the 
subjects in the present study were female. This 
was primarily due to the rarity of invasive ductal 
carcinomas among males. Other investigators have 
encountered this issue as well, and because of this 
reason, the findings of the present study cannot be 
generalised for both sexes.[15] Similarly, there was 
only one case of Grade I breast carcinoma. This 
study was conducted at a single centre in Pakistan, 
which may raise doubts about the generalisability 
of the results. However, this is a tertiary care facility, 
which receives patients from all across Pakistan. The 
pathologist grading the samples did not undergo 
reliability assessment, and they were not blind to 
their colleagues’ reviews. Ideally, at least two highly 
experienced or dedicated breast pathologists 
should do grading blindly and achieve consensus 
or exclude those cases in which discrepancy exists 
to minimise bias. Nonetheless, in this study, grading 
was done independently by two pathologists with 
experience of more than 20 years in histopathology. 
Further studies with larger and more diverse sample 
sizes are required to study the relationship between 
grades of breast cancer and BCL-2 expression.
Conclusion
Approximately half (50%) of the study population 
with invasive ductal carcinoma expressed BCL-2. 
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Although the reduced frequency of BCL-2 
expression was observed with increasing histologic 
grade (i.e., more in low-grade tumours and less 
in Grade III tumours), this was not statistically 
significant.
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